Sierra Oncology

194 articles with Sierra Oncology

• Sierra Oncology Reports First Quarter 2017 Results

  5/9/2017

• Sierra Oncology Collaborator ICR Reports Preclinical Synthetic Lethality Data For Chk1 Inhibitor SRA737 At AACR

  4/3/2017

• Sierra Oncology Reports 2016 Year-End Results

  3/2/2017

• With New Cash and Cancer Targets, Analyst Sees Almost 200% Upside In Sierra Oncology

  2/23/2017

• Sierra Oncology Announces Pricing Of Public Offering Of Common Stock

  2/9/2017

• Sierra Oncology Successfully Transfers Sponsorship Of SRA737 Clinical Trials

  1/9/2017

• ProNAi Therapeutics Relaunched As Sierra Oncology To Advance DDR-Based Cancer Drugs

  1/9/2017

• ProNAi Therapeutics Reports Third Quarter 2016 Results

  11/11/2016

• ProNAi Therapeutics To Present At The 15th Annual BIO Investor Forum In San Francisco

  10/13/2016

• ProNAi Therapeutics Strikes a $328.5 Million Cancer Deal With CRT Pioneer Fund

  9/27/2016

• ProNAi Therapeutics Shuts Down Research Site for Failed Cancer Candidate PNT2258

  8/15/2016

• ProNAi Therapeutics, Inc. Reports Interim Data From Wolverine Phase 2 Trial Of PNT2258 In DLBCL

  6/6/2016

• ProNAi Therapeutics, Inc. Appoints Dr. Christian Hassig As Senior Vice President Of Research

  6/1/2016

• ProNAi Therapeutics, Inc. To Report Wolverine Phase 2 Interim Results On June 6th At ASCO

  5/19/2016

• ProNAi Therapeutics, Inc. Reports First Quarter 2016 Results

  5/10/2016

• ProNAi Therapeutics, Inc. Appoints Jeffrey H. Cooper And Tran Nguyen To Its Board Of Directors

  3/18/2016

• ProNAi Therapeutics, Inc. Granted Orphan Drug Designation For PNT2258 For The Treatment Of Diffuse Large B-Cell Lymphoma

  3/14/2016

• ProNAi Therapeutics, Inc. Reports 2015 Year-End Financial and Operational Results

  3/3/2016

• ProNAi Therapeutics, Inc. To Present At J.P. Morgan 34th Annual Healthcare Conference In San Francisco

  12/22/2015

• ProNAi Therapeutics, Inc. To Present At J.P. Morgan 34th Annual Healthcare Conference In San Francisco

  12/22/2015